The non-hodgkin lymphomas

James R Cerhan, Claire M. Vajdic, John J. Spinelli

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

The non-Hodgkin lymphomas (NHL) are a heterogeneous group of over forty lymphoid neoplasms that have undergone a major redefinition over the last twenty-five years, in part due to advances in immunology and genetics as well as implementation of the WHO classification system. NHLs are considered clonal tumors of B-cells, T-cells, or natural killer (NK) cells arrested at various stages of differentiation, regardless of whether they present in the blood (lymphoid leukemia) or lymphoid tissues (lymphoma). In the United States, the age-standardized NHL incidence rate (per 100,000) doubled from 1973 (10.2) to 2004 (21.4) and then stabilized, while five-year relative survival rates improved from 42% in 1973 to 70% in 2004. Established risk factors for NHL or specific NHL subtypes include infectious agents (HTLV-1, HIV, EBV, HHV8, HCV, H. pylori), immune dysregulation (primary immunodeficiency, transplantation, autoimmunity, and immunosuppressive drugs), family history of lymphoma, and common genetic variants identified by genome-wide association studies.

Original languageEnglish (US)
Title of host publicationSchottenfeld and Fraumeni Cancer Epidemiology and Prevention, Fourth Edition
PublisherOxford University Press
Pages767-796
Number of pages30
ISBN (Electronic)9780190238667
DOIs
StatePublished - Jan 1 2017

Fingerprint

Non-Hodgkin's Lymphoma
Lymphoma
Lymphoid Leukemia
Human T-lymphotropic virus 1
Genome-Wide Association Study
Pylorus
Lymphoid Tissue
Immunosuppressive Agents
Allergy and Immunology
Autoimmunity
Human Herpesvirus 4
Natural Killer Cells
Neoplasms
B-Lymphocytes
Transplantation
HIV
T-Lymphocytes
Incidence
Pharmaceutical Preparations

Keywords

  • B-cell
  • Immunodeficiency
  • Lymphoid leukemia
  • Lymphoma
  • Natural killer cell
  • Non-Hodgkin lymphoma
  • T-cell

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cerhan, J. R., Vajdic, C. M., & Spinelli, J. J. (2017). The non-hodgkin lymphomas. In Schottenfeld and Fraumeni Cancer Epidemiology and Prevention, Fourth Edition (pp. 767-796). Oxford University Press. https://doi.org/10.1093/oso/9780190238667.003.0040

The non-hodgkin lymphomas. / Cerhan, James R; Vajdic, Claire M.; Spinelli, John J.

Schottenfeld and Fraumeni Cancer Epidemiology and Prevention, Fourth Edition. Oxford University Press, 2017. p. 767-796.

Research output: Chapter in Book/Report/Conference proceedingChapter

Cerhan, JR, Vajdic, CM & Spinelli, JJ 2017, The non-hodgkin lymphomas. in Schottenfeld and Fraumeni Cancer Epidemiology and Prevention, Fourth Edition. Oxford University Press, pp. 767-796. https://doi.org/10.1093/oso/9780190238667.003.0040
Cerhan JR, Vajdic CM, Spinelli JJ. The non-hodgkin lymphomas. In Schottenfeld and Fraumeni Cancer Epidemiology and Prevention, Fourth Edition. Oxford University Press. 2017. p. 767-796 https://doi.org/10.1093/oso/9780190238667.003.0040
Cerhan, James R ; Vajdic, Claire M. ; Spinelli, John J. / The non-hodgkin lymphomas. Schottenfeld and Fraumeni Cancer Epidemiology and Prevention, Fourth Edition. Oxford University Press, 2017. pp. 767-796
@inbook{08eac016d58a456f906281a74a4f9eed,
title = "The non-hodgkin lymphomas",
abstract = "The non-Hodgkin lymphomas (NHL) are a heterogeneous group of over forty lymphoid neoplasms that have undergone a major redefinition over the last twenty-five years, in part due to advances in immunology and genetics as well as implementation of the WHO classification system. NHLs are considered clonal tumors of B-cells, T-cells, or natural killer (NK) cells arrested at various stages of differentiation, regardless of whether they present in the blood (lymphoid leukemia) or lymphoid tissues (lymphoma). In the United States, the age-standardized NHL incidence rate (per 100,000) doubled from 1973 (10.2) to 2004 (21.4) and then stabilized, while five-year relative survival rates improved from 42{\%} in 1973 to 70{\%} in 2004. Established risk factors for NHL or specific NHL subtypes include infectious agents (HTLV-1, HIV, EBV, HHV8, HCV, H. pylori), immune dysregulation (primary immunodeficiency, transplantation, autoimmunity, and immunosuppressive drugs), family history of lymphoma, and common genetic variants identified by genome-wide association studies.",
keywords = "B-cell, Immunodeficiency, Lymphoid leukemia, Lymphoma, Natural killer cell, Non-Hodgkin lymphoma, T-cell",
author = "Cerhan, {James R} and Vajdic, {Claire M.} and Spinelli, {John J.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1093/oso/9780190238667.003.0040",
language = "English (US)",
pages = "767--796",
booktitle = "Schottenfeld and Fraumeni Cancer Epidemiology and Prevention, Fourth Edition",
publisher = "Oxford University Press",
address = "United States",

}

TY - CHAP

T1 - The non-hodgkin lymphomas

AU - Cerhan, James R

AU - Vajdic, Claire M.

AU - Spinelli, John J.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The non-Hodgkin lymphomas (NHL) are a heterogeneous group of over forty lymphoid neoplasms that have undergone a major redefinition over the last twenty-five years, in part due to advances in immunology and genetics as well as implementation of the WHO classification system. NHLs are considered clonal tumors of B-cells, T-cells, or natural killer (NK) cells arrested at various stages of differentiation, regardless of whether they present in the blood (lymphoid leukemia) or lymphoid tissues (lymphoma). In the United States, the age-standardized NHL incidence rate (per 100,000) doubled from 1973 (10.2) to 2004 (21.4) and then stabilized, while five-year relative survival rates improved from 42% in 1973 to 70% in 2004. Established risk factors for NHL or specific NHL subtypes include infectious agents (HTLV-1, HIV, EBV, HHV8, HCV, H. pylori), immune dysregulation (primary immunodeficiency, transplantation, autoimmunity, and immunosuppressive drugs), family history of lymphoma, and common genetic variants identified by genome-wide association studies.

AB - The non-Hodgkin lymphomas (NHL) are a heterogeneous group of over forty lymphoid neoplasms that have undergone a major redefinition over the last twenty-five years, in part due to advances in immunology and genetics as well as implementation of the WHO classification system. NHLs are considered clonal tumors of B-cells, T-cells, or natural killer (NK) cells arrested at various stages of differentiation, regardless of whether they present in the blood (lymphoid leukemia) or lymphoid tissues (lymphoma). In the United States, the age-standardized NHL incidence rate (per 100,000) doubled from 1973 (10.2) to 2004 (21.4) and then stabilized, while five-year relative survival rates improved from 42% in 1973 to 70% in 2004. Established risk factors for NHL or specific NHL subtypes include infectious agents (HTLV-1, HIV, EBV, HHV8, HCV, H. pylori), immune dysregulation (primary immunodeficiency, transplantation, autoimmunity, and immunosuppressive drugs), family history of lymphoma, and common genetic variants identified by genome-wide association studies.

KW - B-cell

KW - Immunodeficiency

KW - Lymphoid leukemia

KW - Lymphoma

KW - Natural killer cell

KW - Non-Hodgkin lymphoma

KW - T-cell

UR - http://www.scopus.com/inward/record.url?scp=85051026488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051026488&partnerID=8YFLogxK

U2 - 10.1093/oso/9780190238667.003.0040

DO - 10.1093/oso/9780190238667.003.0040

M3 - Chapter

SP - 767

EP - 796

BT - Schottenfeld and Fraumeni Cancer Epidemiology and Prevention, Fourth Edition

PB - Oxford University Press

ER -